R. Theriault

发表

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

J. Ross, K. Hess, G. Hortobagyi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Revision of the American Joint Committee on Cancer staging system for breast cancer.

Donald L Weaver, Kirby I Bland, Gary Clark, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1991, Journal of the National Cancer Institute.

Choosing Hormone Replacement Therapy

R. Theriault, Laura L. Boehnke, R. Sellin, 1995 .

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Patrick Soon-Shiong, Neil Desai, G. Hortobagyi, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience

G. Hortobagyi, N. Ibrahim, R. Theriault, 1999, Cancer Chemotherapy and Pharmacology.

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

R. Theriault, R. Beveridge, R. Weiss, 2000, The Lancet.

Estrogen R eplacement T herapy A fter L ocalized B reast Cancer: C linical O utcome o f 3 19 W omen Followed P rospectively

G. Hortobagyi, S. Singletary, R. Theriault, 2006 .

Estrogen replacement therapy for menopausal women with a history of breast carcinoma

Terry L. Smith, G. Hortobagyi, S. Singletary, 2002, Cancer.

Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively.

G. Hortobagyi, S. Singletary, R. Theriault, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Institutional Analysis of the Socioeconomic Determinants of Breast Reconstruction: A Study of the National Comprehensive Cancer Network

Caprice K. Christian, J. Niland, S. Edge, 2006, Annals of surgery.

A clinical dilemma: estrogen replacement therapy in postmenopausal women with a background of primary breast cancer.

R. Theriault, R. Sellin, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Pregnancy after the diagnosis of breast cancer.

R. Theriault, P. K. Morrow, 2006, Clinical breast cancer.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma

G. Hortobagyi, R. Theriault, A. Buzdar, 2004, Cancer.

Treatment choices and response rates in African‐American women with breast carcinoma

L. Newman, R. Theriault, L. Pierce, 2003, Cancer.

Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer.

R. Theriault, R. Vassilopoulou-sellin, 1994, Journal of the National Cancer Institute. Monographs.

Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.

G. Hortobagyi, S. Singletary, T. Buchholz, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locoregional R ecurrence P atterns A fter M astectomy a nd Doxorubicin-Base d C hemotherapy: I mplications f or Postoperative I rradiation

G. Hortobagyi, S. Singletary, T. Buchholz, 2000 .

Breast Cancer, Version 3.2013

B. Ljung, D. Mankoff, S. Edge, 2013 .

The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy

G. Hortobagyi, R. Theriault, A. Buzdar, 1989, Cancer.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

J. Herman, J. Niland, J. Vandergrift, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

G. Hortobagyi, N. Sneige, V. Valero, 2011, The oncologist.

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

V. Valero, R. Theriault, R. Carlson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

J. Niland, S. Edge, R. Theriault, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.

J. Niland, S. Edge, R. Theriault, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid (Zometa®) use in bone disease

R. Theriault, 2003, Expert review of anticancer therapy.

The impact of breast reconstruction on the delivery of chemotherapy

J. Niland, S. Edge, R. Theriault, 2010, Cancer.

Breast cancer during pregnancy.

R. Theriault, K. Gwyn, Richard Theriault, 2001, Oncology.

Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation.

S. Singletary, T. Buchholz, R. Theriault, 2001, International journal of radiation oncology, biology, physics.

Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up.

G. Hortobagyi, N. Ibrahim, R. Theriault, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer during pregnancy.

R. Theriault, K. Gwyn, 2000, Current treatment options in oncology.

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery

S. Lipsitz, Wei Jiang, J. Niland, 2018, Breast Cancer Research and Treatment.

Breast Cancer

B. Ljung, E. Winer, S. Edge, 2023, M.D. Anderson Solid Tumor Oncology Series.

The effect of age on delay in diagnosis and stage of breast cancer.

E. Winer, J. Niland, S. Edge, 2012, The oncologist.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

L. Neumayer, R. Theriault, H. Rugo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers

E. Winer, S. Edge, R. Theriault, 2016, Breast Cancer Research and Treatment.

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer

G. Hortobagyi, V. Valero, R. Theriault, 2015, Journal of Cancer.

Biology of bone metastases.

R. Theriault, R. Theriault, 2012, Cancer control : journal of the Moffitt Cancer Center.

Bone Metastasis of Breast Cancer.

G. Hortobagyi, R. Theriault, N. Ueno, 2013 .

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study

E. Winer, S. Edge, R. Theriault, 2015, Cancer.

A prospective study of bone tumor response assessment in metastatic breast cancer.

G. Hortobagyi, R. Theriault, N. Ueno, 2013, Clinical breast cancer.

Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.

E. Winer, J. Niland, S. Edge, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment

R. Theriault, J. Litton, 2010, The oncologist.

The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy.

S. Singletary, T. Buchholz, R. Theriault, 2001, International journal of radiation oncology, biology, physics.

Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

R. Theriault, F. Esteva, Yu Shen, 2007, Breast Cancer Research and Treatment.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

M. Somerfield, R. Jagsi, R. Theriault, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of radiation use as a component of breast conservation therapy for noninvasive and invasive breast cancers in united states national comprehensive cancer network (nccn) centers

S. Edge, T. Buchholz, R. Theriault, 2003 .

Synchronous primary cancers of the breast and cervix: planning multidisciplinary primary treatment [clinico-pathological conference].

C. L. Edwards, M. Ross, R. Theriault, 2000, American journal of clinical oncology.

Breast carcinoma during pregnancy

P. Ellis, R. Theriault, S. Loibl, 2006, Cancer.

Factors associated with appropriate use of radiation therapy after mastectomy in women with Stage I-II breast cancer treated within the National Comprehensive Cancer Network (NCCN).

J. Niland, S. Edge, R. Theriault, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of age on delay in diagnosis and stage of breast cancer.

E. Winer, J. Niland, S. Edge, 2010, The oncologist.

Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.

J. Niland, S. Edge, R. Theriault, 2008, International journal of radiation oncology, biology, physics.

Feasibility of Immediate Breast Reconstruction for Locally Advanced Breast Cancer

G. Robb, S. Singletary, M. Ross, 1999, Annals of Surgical Oncology.

Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer

R. Theriault, R. Vassilopoulou-sellin, M. Klein, 1997, Gynecologic oncology.

Multidisciplinary management of breast cancer concurrent with pregnancy.

S. Singletary, H. Kuerer, F. Ames, 2002, Journal of the American College of Surgeons.

Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

E. Winer, A. Vanderplas, J. Niland, 2012, Cancer.

Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy

Terry L. Smith, G. Hortobagyi, R. Theriault, 1999, Cancer.

Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.

Jingfei Ma, Naoto T Ueno, G. Hortobagyi, 2009, The Lancet. Oncology.

The evolving role of bisphosphonates.

G. Hortobagyi, R. Theriault, 2001, Seminars in oncology.

Markers of bone resorption in patients treated with pamidronate.

G. Hortobagyi, R. Theriault, V. Chinchilli, 1998, European journal of cancer.

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis

G. Hortobagyi, R. Theriault, N. Ueno, 2011, The oncologist.

Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease

R. Theriault, Z. Gokaslan, L. Rhines, 2007, European Spine Journal.

Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients

R. Theriault, Z. Gokaslan, L. Rhines, 2007, European Spine Journal.

Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone‐only metastases

G. Hortobagyi, R. Theriault, N. Ueno, 2012, Cancer.

Bisphosphonates: ready for use as adjuvant therapy of breast cancer?

R. Theriault, 2010, Current opinion in obstetrics & gynecology.

Markers of bone resorption in patients treated with pamidronate

G. Hortobagyi, R. Theriault, L. Demers, 1995 .

Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases.

H. Libshitz, R. Theriault, D. Podoloff, 1998, Journal of pain and symptom management.

A Retrospective Study of First Indicators of Breast Cancer Recurrence

G. Hortobagyi, R. Theriault, A. Buzdar, 2000, Oncology.

Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy.

W. Woodward, T. Buchholz, R. Theriault, 2005, International journal of radiation oncology, biology, physics.

Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers.

Rebecca Ottesen, Joyce C Niland, Jane C Weeks, 2003, Journal of the National Cancer Institute.

The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy

G. Hortobagyi, S. Singletary, J. Garcia-conde, 2005, Cancer.

Comparative effectiveness of stereotactic radiosurgery versus whole‐brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer

H. Uno, J. Niland, S. Edge, 2016, Cancer.

Thyroid hormone and breast carcinoma

G. Hortobagyi, R. Theriault, S. Krishnamurthy, 2005, Cancer.

Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2011 .

American Society of Clinical Oncology Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2011 .

Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?

J. Niland, S. Edge, R. Theriault, 2011, The oncologist.

Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy.

R. Theriault, M. Fanale, A. Uyei, 2005, Clinical breast cancer.

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

G. Hortobagyi, R. Theriault, J. Simeone, 2000, Cancer.

The Safety of Chemotherapy for Breast Cancer Patients with Hepatitis C Virus Infection

R. Theriault, A. Shimomura, H. Kumada, 2013, Journal of Cancer.

Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone as Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-up Results of the French Adjuvant Study Group 08 Trial

R. Theriault, 2005 .

Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia

R. Theriault, R. Benjamin, L. Elting, 2006, Cancer.

Pathophysiology and implications of cancer treatment-induced bone loss.

R. Theriault, 2004, Oncology.

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?

V. Valero, D. Booser, R. Theriault, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of breast cancer during pregnancy using a standardized protocol.

D. L. Berry, G. Hortobagyi, S. Singletary, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine for 5‐Fluorouracil‐Resistant Brain Metastases From Breast Cancer

Michael L. Wang, W. Yung, R. Theriault, 2001, American journal of clinical oncology.

Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1997, Seminars in oncology.

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

G. Hortobagyi, H. Gibbs, V. Valero, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N1) platinum in patients with metastatic solid tumors

R. Theriault, M. Raber, C. Kowal, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

G. Hortobagyi, R. Theriault, F. Holmes, 1996, Cancer Chemotherapy and Pharmacology.

Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Breast cancer. Clinical practice guidelines in oncology.

Krystyna Kiel, Mohammad Jahanzeb, Ingrid A Mayer, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature

V. Valero, N. Ibrahim, R. Theriault, 2014, Journal of Cancer.

Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.

Kelly K Hunt, W. Woodward, G. Hortobagyi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation

R. Bast, G. Hortobagyi, V. Valero, 2001, Cancer investigation.

Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma

R. Bast, G. Hortobagyi, V. Valero, 1999, Cancer.

Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy

G. Hortobagyi, J. Wathen, V. Valero, 2004, Cancer.

Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer

G. Hortobagyi, R. Theriault, A. Buzdar, 1988, Cancer.

Long-term efficacy and late sequelae of Doxorubicin containing adjuvant therapy for breast cancer : MD Anderson Cancer Center studies

G. Hortobagyi, S. Singletary, R. Theriault, 1994 .

Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN).

E. Winer, A. Vanderplas, J. Niland, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.

G. Hortobagyi, S. Singletary, F. Ames, 1997, Seminars in oncology.

19 Breast Cancer During Pregnancy

R. Theriault, 1999 .

Changes i n t he 2 003 A merican J oint C ommittee o n C ancer Staging f or B reast C ancer D ramatically A ffect S tage-Specific Survival

W. Woodward, G. Hortobagyi, S. Singletary, 2003 .

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary chemotherapy for breast cancer : response to preoperative chemotherapy as prognostic factor

G. Hortobagyi, S. Singletary, F. Ames, 1994 .

Primary chemotherapy for breast cancer — MD Anderson experience

G. Hortobagyi, S. Singletary, N. Sneige, 1991 .

Breast Cancer Treatment During Pregnancy

R. Theriault, A. Rieber, 2005, Women's health.

Differentiating inflammatory breast cancer from acute mastitis.

R. Theriault, J. Donnelly, S. Dahlbeck, 1995, American family physician.

Phase I and Pharmacokinetic Study of ABI-007 , a Cremophor-free , Protein-stabilized , Nanoparticle Formulation of Paclitaxel 1

G. Hortobagyi, N. Ibrahim, R. Theriault, 2002 .

Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.

M. Ross, R. Theriault, A. González-Angulo, 2004, Clinical breast cancer.

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

G. Hortobagyi, H. Gibbs, V. Valero, 1993, Journal of the National Cancer Institute. Monographs.

Combined modality approach in treatment of inflammatory carcinoma of the breast MD Anderson Cancer Center experience

G. Hortobagyi, R. Theriault, A. Buzdar, 1991 .

Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1986, Cancer treatment reports.

Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1997, Seminars in oncology.

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.

D. Larsimont, M. Piccart, G. Hortobagyi, 2009 .

Outcomes of children exposed in utero to chemotherapy for breast cancer

G. Hortobagyi, V. Valero, R. Theriault, 2014, Breast Cancer Research.

Management of breast cancer during pregnancy using a standardized protocol.

D. L. Berry, G. Hortobagyi, S. Singletary, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to D. Crivellari et al.

R. Theriault, J. Litton, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?

R. Theriault, J. Litton, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer

G. Hortobagyi, R. Theriault, A. Buzdar, 1990, American Journal of Clinical Oncology.

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

D. Berry, G. Hortobagyi, R. Theriault, 2010, British Journal of Cancer.

Mammography capacity impact on screening rates and breast cancer stage at diagnosis.

R. Theriault, L. Elting, S. Giordano, 2009, American journal of preventive medicine.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

B. Ljung, D. Mankoff, S. Edge, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

W. Woodward, G. Hortobagyi, L. Pusztai, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.

J. Stec, M. Ayers, K. Hess, 2005, Endocrine-related cancer.

Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero

G. Hortobagyi, H. Kuerer, R. Theriault, 2006, Cancer.

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

G. Hortobagyi, S. Singletary, F. Ames, 1997, Cancer Chemotherapy and Pharmacology.

Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy.

G. Hortobagyi, R. Theriault, R. Vassilopoulou-sellin, 1998, Cancer investigation.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Amy M. Sitapati, B. Ljung, D. Mankoff, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.

D. Chan, G. Hortobagyi, R. Theriault, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Recombinant α‐Interferon (rIFNα) and Continuous‐Infusion 5‐Fluorouracil in Metastatic Breast Cancer

G. Hortobagyi, D. Booser, R. Theriault, 1995 .

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer.

G. Hortobagyi, D. Booser, R. Theriault, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase II study of recombinant α-interferon and recombinant interleukin-2 in metastatic breast cancer

G. Hortobagyi, R. Theriault, F. Holmes, 1994 .

Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer.

G. Hortobagyi, R. Theriault, F. Holmes, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

G. Hortobagyi, N. Sneige, V. Valero, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma

G. Hortobagyi, F. Ames, V. Valero, 2003, Cancer.

The role of bisphosphonates in breast cancer.

R. Theriault, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

J. Stec, M. Ayers, K. Hess, 2003, Cancer.

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Terry L. Smith, D. Berry, G. Hortobagyi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Funda Meric-Bernstam, Kristine R Broglio, Denis Larsimont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

E. Winer, S. Edge, R. Theriault, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future directions of bone-targeted therapy for metastatic breast cancer

G. Hortobagyi, R. Theriault, N. Ueno, 2010, Nature Reviews Clinical Oncology.

Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells.

R. Theriault, J. Price, R. Mukhopadhyay, 1999, Clinical & experimental metastasis.

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.

G. Hortobagyi, N. Sneige, H. Kuerer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased levels of α6 integrins are associated with the metastatic phenotype of human breast cancer cells

R. Theriault, J. Price, R. Mukhopadhyay, 1999, Clinical & Experimental Metastasis.

‘Chemobrain’ in breast carcinoma?

R. Theriault, A. Buzdar, R. Lenzi, 2004, Cancer.

Acquired immunodeficiency syndrome-associated malignancies

R. Theriault, 1989, The Journal of the American Osteopathic Association.

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.

Rulla M Tamimi, Yu-Ning Wong, Joyce C Niland, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Metastasis of Breast Cancer.

R. Theriault, N. Ueno, T. Brewer, 2019, Advances in experimental medicine and biology.

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.

S. Edge, S. Singletary, L. Bassett, 2003, The Surgical clinics of North America.

Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy.

R. Theriault, W. Yang, G. Whitman, 2006, Radiology.

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Roman Rouzier, Lajos Pusztai, G. Hortobagyi, 2005, Cancer.

The impact of pregnancy on breast cancer outcomes in women ≤35 years

W. Woodward, T. Buchholz, R. Theriault, 2009, Cancer.

Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.

G. Hortobagyi, H. Kuerer, R. Theriault, 2013, The oncologist.

Wound complications from surgery in pregnancy-associated breast cancer (PABC).

G. Hortobagyi, H. Kuerer, G. Babiera, 2010, Breast disease.

Breast carcinoma in pregnant women

R. Theriault, A. Sahin, M. Amin, 2003, Cancer.

Systemic Treatment During Pregnancy

R. Theriault, J. Litton, 2010 .

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

J. V. Von Roenn, R. Theriault, B. Hillner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Independent validation of apache ii severity of illness score for predicting mortality in patients with breast cancer admitted to the intensive care unit

R. Theriault, R Theriault, J Headley, 1992, Cancer.

Effects of race and socioeconomic status on survival of 1,332 black, hispanic, and white women with breast cancer

S. Singletary, R. Theriault, L. Franzini, 1997, Annals of Surgical Oncology.

Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.

G. Hortobagyi, S. Singletary, F. Ames, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy

G. Hortobagyi, S. Singletary, V. Valero, 2000, Cancer.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Terry L. Smith, G. Hortobagyi, S. Singletary, 2000, Journal of the National Cancer Institute.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

G. Hortobagyi, S. Singletary, N. Sneige, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

V. Valero, R. Theriault, J. Murray, 2010, British Journal of Cancer.

FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.

G. Hortobagyi, Jun Liu, R. Theriault, 2011, The oncologist.

Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy.

R. Theriault, A. Buzdar, 1990, Medical and pediatric oncology.

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Terry L. Smith, G. Hortobagyi, L. Pusztai, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

Terry L. Smith, D. Berry, G. Hortobagyi, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

G. Hortobagyi, S. Singletary, F. Ames, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective E valuation o f P aclitaxel V ersus C ombination Chemotherapy W ith F luorouracil, D oxorubicin, and C yclophosphamide a s N eoadjuvant T herapy i n P atients With O perable B reast C ancer

G. Hortobagyi, S. Singletary, F. Ames, 1999 .

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

G. Hortobagyi, L. Pusztai, V. Valero, 1998, American journal of clinical oncology.

Taxol in metastatic breast cancer the MD Anderson Cancer Center experience

G. Hortobagyi, H. Gibbs, V. Valero, 1994 .

Female patients with breast carcinoma age 30 years and younger have a poor prognosis

G. Hortobagyi, V. Valero, R. Theriault, 2001, Cancer.

Phase I trail of droloxifene in patients with metastatic breast cancer

G. Hortobagyi, D. Booser, R. Theriault, 2004, Cancer Chemotherapy and Pharmacology.

Combined‐modality treatment for isolated recurrences of breast carcinoma

Massimo Cristofanilli, G. Hortobagyi, V. Valero, 2005, Cancer.

Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease

G. Hortobagyi, R. Theriault, A. Buzdar, 2002, The breast journal.

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.

G. Hortobagyi, V. Valero, R. Theriault, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypercalcemia of malignancy: pathophysiology and implications for treatment.

R. Theriault, 1993, Oncology.

Metastatic lobular breast carcinoma simulating primary colon cancer.

R. Theriault, C. Balch, N. Voravud, 1992, American journal of clinical oncology.

Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network

N. Keating, R. Theriault, J. Weeks, 2013, Cancer.

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

J. Niland, R. Theriault, H. Rugo, 2012, Breast Cancer Research.

Breast cancer treatment guidelines in older women.

G. Hortobagyi, R. Theriault, S. Giordano, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Special Clinical Situations in Patients with Breast Cancer

R. Theriault, K. Hahn, 2008 .

Aromatase inhibitors in postmenopausal breast cancer patients.

R. Theriault, A. Rieber, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Management of breast cancer in pregnancy

R. Theriault, K. Hahn, 2007, Current oncology reports.

Conservative surgery and chemotherapy for breast carcinoma during pregnancy.

H. Kuerer, F. Ames, R. Theriault, 2002, Surgery.

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer

G. Hortobagyi, R. Theriault, F. Holmes, 1992, Investigational New Drugs.

Phase II study of deoxyspergualin in metastatic breast cancer

G. Hortobagyi, V. Valero, D. Booser, 2004, Investigational New Drugs.

NCCN Task Force Report: Bone Health and Cancer Care.

C. Shapiro, R. Theriault, D. Podoloff, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions.

Yu-Ning Wong, Joyce C Niland, Jane C Weeks, 2013, Journal of the National Cancer Institute.

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

V. Valero, R. Theriault, A. Buzdar, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Diagnosis during Pregnancy

R. Theriault, A. González-Angulo, J. Litton, 2009, Women's health.

Phase II study of taxotere in refractory metastatic breast cancer (RMBC)

G. Hortobagyi, V. Valero, R. Theriault, 1993 .

Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2.

R. Theriault, R. Vassilopoulou-sellin, A. Sella, 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.

C. Hudis, L. Norton, D. Booser, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I–II study of high-dose etoposide in patients with refractory breast cancer

G. Hortobagyi, R. Theriault, A. Buzdar, 1991, Investigational New Drugs.

Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.

G. Hortobagyi, R. Theriault, L. Schover, 2014, The oncologist.

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin‐containing adjuvant therapy

G. Hortobagyi, S. Singletary, F. Ames, 1992, Cancer.

Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2013 .

NCCN Practice Guidelines for Breast Cancer.

E. Winer, S. Edge, W. Gradishar, 2000, Oncology.

Comparison of baseline dietary intake of Hispanic and matched non-Hispanic white breast cancer survivors enrolled in the Women's Healthy Eating and Living study.

R. Theriault, J. Pierce, R. Hajek, 2008, Journal of the American Dietetic Association.

Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004

R. Theriault, Yu Shen, P. Ravdin, 2009, Cancer.

Strategies to prevent chemotherapy-induced bone loss in women with breast cancer.

R. Theriault, 2005, Clinical breast cancer.

Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control?

S. Singletary, T. Buchholz, R. Theriault, 1999, International journal of radiation oncology, biology, physics.

Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN)

J. Niland, S. Edge, R. Theriault, 2008 .

The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma

R. Theriault, R. Lenzi, C. Meyers, 2004, Cancer.

Revision o f t he A merican J oint C ommittee o n C ancer Staging S ystem f or B reast C ancer

S. Edge, S. Singletary, L. Bassett, 2011 .

Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.

Diane D. Liu, V. Valero, R. Theriault, 2015, Clinical breast cancer.

Selecting High Priority Quality Measures For Breast Cancer Quality Improvement

J. Niland, S. Edge, R. Theriault, 2008, Medical care.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

E. Winer, E. Perez, C. Hudis, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Institutional Variation in the Surgical Treatment of Breast Cancer: A Study of the NCCN

S. Lipsitz, J. Niland, S. Edge, 2011, Annals of surgery.

Prognostic Role of Detection Method and Its Relationship with Tumor Biomarkers in Breast Cancer: The University of Texas M. D. Anderson Cancer Center Experience

D. Berry, R. Theriault, Yu Shen, 2008, Cancer Epidemiology Biomarkers & Prevention.

Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.

Lurdes Y. T. Inoue, D. Berry, L. Inoue, 2006, Journal of the National Cancer Institute. Monographs.

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.

G. Hortobagyi, B. Fornage, H. Kuerer, 2016, JAMA oncology.

Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network.

E. Winer, S. Edge, W. Gradishar, 1999, Oncology.

Effects of chronic hepatitis C infection on the treatment of breast cancer patients.

R. Theriault, J. Tarrand, K. Broglio, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ

Wei Jiang, J. Niland, S. Edge, 2012, Cancer.

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.

Terry L. Smith, G. Hortobagyi, S. Singletary, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 2008, Clinical breast cancer.

Women age < or = 35 years with primary breast carcinoma: disease features at presentation.

Kristine Broglio, G. Hortobagyi, V. Valero, 2005, Cancer.

Women age ≤ 35 years with primary breast carcinoma

G. Hortobagyi, V. Valero, D. Booser, 2005 .

Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

G. Hortobagyi, R. Theriault, N. Ueno, 2011, The oncologist.

JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines

E. Winer, E. Perez, C. Hudis, 2006 .

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers

S. Edge, C. Hudis, R. Theriault, 2011, Breast Cancer Research and Treatment.

Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ

S. Singletary, M. Ross, H. Kuerer, 2004, Cancer.

Trastuzumab treatment and the risk of central nervous system (CNS) metastases

G. Hortobagyi, R. Theriault, F. Esteva, 2007 .

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

G. Hortobagyi, V. Valero, D. Booser, 2000, Cancer.

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.

H. Uno, J. Niland, S. Edge, 2015, International journal of radiation oncology, biology, physics.

Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2006, Cancer.

Estrogen-replacement therapy in younger women with breast cancer.

R. Theriault, R. Sellin, 1994, Journal of the National Cancer Institute. Monographs.

The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™

Lawrence B. Marks, Robert W. Carlson, Daniel F. Hayes, 2007 .

Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.

J. Niland, S. Edge, H. Kuerer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer

V. Valero, D. Booser, R. Theriault, 2004, Clinical Cancer Research.

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.

R. Bast, G. Hortobagyi, V. Valero, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.

Wei Jiang, J. Niland, S. Edge, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Inflammatory carcinoma of the breast: results of a combined-modality approach — M. D. Anderson Cancer Center experience

G. Hortobagyi, S. Singletary, F. Ames, 1990, Cancer Chemotherapy and Pharmacology.

NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network.

W. Gradishar, R. Theriault, R. Carlson, 1996, Oncology.

Patient perspectives on breast cancer treatment plan and summary documents in community oncology care

Anne Moore, J. Griggs, R. Theriault, 2013, Cancer.

The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers.

J. Niland, S. Edge, T. Buchholz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone biology and the role of the RANK ligand pathway.

R. Theriault, P. K. Morrow, R. Murthy, 2009, Oncology.

Ethnic disparities in adherence to breast cancer survivorship surveillance care

R. Theriault, I. Bedrosian, S. Moulder, 2014, Cancer.

Invasive breast cancer.

B. Ljung, E. Winer, S. Edge, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Time to diagnosis and breast cancer stage by race/ethnicity

E. Winer, J. Niland, S. Edge, 2012, Breast Cancer Research and Treatment.

Breast carcinoma during pregnancy. International recommendations from an expert meeting.

P. Ellis, R. Theriault, S. Loibl, 2006, Cancer.

Breast cancer and second primary ovarian cancer in dermatomyositis.

G. Hortobagyi, M. Dimopoulos, R. Theriault, 1991, Gynecologic oncology.

NCCN: Breast cancer.

S. Edge, R. Theriault, R. Carlson, 2001, Cancer control : journal of the Moffitt Cancer Center.

Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients before and after Cytotoxic Chemotherapy or Targeted Therapy

R. Theriault, C. Charnsangavej, W. Yang, 2015, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

In reply [18]

G. Hortobagyi, R. Theriault, A. Buzdar, 2005 .

Development of New Cancers in Patients with DCIS: The M.D. Anderson Experience

G. Hortobagyi, F. Meric, R. Theriault, 2007, Annals of Surgical Oncology.

Ethical Concerns When Cancer Patients Become Human Research Participants and Are Treated on Clinical Trials

R. Theriault, 2017 .

P2-13-05: Breast Cancer, BRCA Mutations and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis.

G. Hortobagyi, R. Theriault, L. Schover, 2011 .

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis

G. Hortobagyi, V. Valero, D. Booser, 2004 .

Commentary: Ovarian function does not equal fertility does not equal babies.

R. Theriault, H. Moore, 2007, The oncologist.

Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2005 .

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, H. Wheeler, 1996, The New England journal of medicine.

PP-8-8 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (AREDIA®) infusion

R. Theriault, J. Simeone, S. Glück, 1996 .

The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero

G. Hortobagyi, H. Kuerer, R. Theriault, 2005 .

J. Niland, R. Theriault, H. Rugo, 2012, Breast Cancer Research.

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, J. Simeone, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).

J. Niland, R. Theriault, H. Rugo, 2012 .

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, H. Wheeler, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer during pregnancy

R. Theriault, K. Gwyn, 2000, Current treatment options in oncology.

Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.

R. Theriault, R. Navari, S. Madajewicz, 1994, Archives of internal medicine.

Use of Taxol (paclitaxel) in breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1994, Oncology.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

B. Ljung, D. Mankoff, S. Edge, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

E. Winer, A. Vanderplas, J. Niland, 2012, Cancer.

Phase I S tudy o f S tealth L iposomal D oxorubicin i n Combination W ith G emcitabine i n t he T reatment o f Patients W ith M etastatic B reast C ancer

R. Bast, G. Hortobagyi, V. Valero, 2001 .

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

W. Woodward, G. Hortobagyi, L. Pusztai, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Ethnic disparities in adherence to breast cancer survivorship surveillance care

R. Theriault, I. Bedrosian, S. Moulder, 2014, Cancer.

Ethnic disparities in adherence to breast cancer survivorship care.

R. Theriault, S. Moulder, A. Brewster, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.

J. Stec, M. Ayers, K. Hess, 2005, Endocrine-related cancer.

Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?

R. Theriault, 2012, The oncologist.

Selecting High Priority Quality Measures For Breast Cancer Quality Improvement

J. Niland, S. Edge, R. Theriault, 2008, Medical Care.

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.

J. Niland, R. Theriault, M. Hughes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of obesity on adherence to the National Comprehensive Cancer Network (NCCN) guidelines recommending chemotherapy for patients with operable breast cancer.

S. Edge, C. Hudis, R. Theriault, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.